The main topic is the collaboration between C2i Genomics and Tel Aviv Sourasky Medical Center to enable early detection of recurring cancer using a cloud-based AI solution.
Key points:
1. C2i Genomics' MRD testing improves cancer detection and monitoring by analyzing blood test data in the cloud using AI and genomic databases.
2. Ichilov Hospital will incorporate C2i Genomics' technology into clinical examinations and sees MRD testing as a transformative approach in oncology.
3. C2i Genomics aims to commercialize its testing method and is already collaborating with pharmaceutical companies for clinical trials and drug development.
Google DeepMind has commissioned 13 artists to create diverse and accessible art and imagery that aims to change the public’s perception of AI, countering the unrealistic and misleading stereotypes often used to represent the technology. The artwork visualizes key themes related to AI, such as artificial general intelligence, chip design, digital biology, large image models, language models, and the synergy between neuroscience and AI, and it is openly available for download.
Artificial intelligence (AI) has the potential to greatly improve health care globally by expanding access to health services, according to Google's chief health officer, Karen DeSalvo. Through initiatives such as using AI to monitor search queries for potential self-harm, as well as developing low-cost ultrasound devices and automated screening for tuberculosis, AI can address health-care access gaps and improve patient outcomes.
DeepMind, in partnership with Google Cloud, has developed SynthID, a tool for watermarking and identifying AI-generated images, specifically those created by Google's image-generating model Imagen, in an effort to empower people with knowledge of AI-generated content and prevent the spread of misinformation.
The AI Insight Forum, led by Chuck Schumer, is set to discuss artificial intelligence regulations with tech industry giants, although it has faced criticism for its exclusion of common voices; meanwhile, Google's DeepMind has launched a beta version of SynthID, a watermarking tool for identifying synthetic content in generative AI.
An AI-generated COVID drug enters clinical trials, GM and Google strengthen their AI partnership, and Israel unveils an advanced AI-powered surveillance plane, among other AI technology advancements.
Researchers have used artificial intelligence to diagnose and predict the risk of developing various diseases, including Parkinson's disease and heart failure, by analyzing images of a person's retinas, achieving better results than previous AI models; meanwhile, a "Pandora's box" of new protein shapes has been discovered through the analysis of over 200 million predicted protein structures.
Google announced its upcoming AI system, Gemini, at the Google I/O developer conference, which combines the strengths of DeepMind's AlphaGo with extensive language modeling capabilities and aims to outperform AI systems like ChatGPT from OpenAI, potentially revolutionizing interactive AI.
Major drugmakers are using artificial intelligence (AI) to accelerate drug development by quickly finding patients for clinical trials and reducing the number of participants needed, potentially saving millions of dollars. AI is increasingly playing a substantial role in human drug trials, with companies such as Amgen, Bayer, and Novartis using AI tools to scan vast amounts of medical data and identify suitable trial patients, significantly reducing the time and cost of recruitment. The use of AI in drug development is on the rise, with the US FDA receiving over 300 applications that incorporate AI or machine learning in drug development from 2016 through 2022.
Deep Genomics has released its AI foundation model, BigRNA, which accurately predicts RNA expression mechanisms and binding sites, as well as the effects of genetic variants and therapeutic candidates, potentially revolutionizing drug discovery and RNA therapeutics.
Concentric by Ginkgo, the biosecurity and public health unit of Ginkgo Bioworks, will partner with Northeastern University to develop new AI-based technologies for epidemic forecasting as part of a consortium funded by the Centers for Disease Control and Prevention.
Researchers have successfully used artificial intelligence (AI) tools, such as AlphaFold, to map the structure of a protein from the Langya henipavirus, a virus related to some deadly pathogens, allowing them to develop a prototype vaccine and highlighting the potential of AI in preparing for future pandemics.
Researchers from Harvard Medical School and the University of Oxford have developed an artificial intelligence tool called EVEscape, which can predict the emergence of new viral variants, including those of SARS-CoV-2, HIV, and influenza, providing valuable information for the development of vaccines and therapies.
A new AI tool called EVEscape uses evolutionary and biological information to predict how a virus could change to escape the immune system, potentially aiding in the development of vaccines and therapies for SARS-CoV-2 and other rapidly mutating viruses.
Researchers from the University of California San Diego have mapped gene switches in different types of brain cells, identifying the links between specific cell types and neuropsychiatric disorders, and using AI to predict the effects of high-risk gene variants.
DeepMind, the Google-owned AI lab, is using artificial intelligence to tackle climate change by helping understand climate change through prediction and monitoring, optimizing existing systems and infrastructure, and accelerating breakthrough science, such as nuclear fusion. The lab also acknowledges the carbon footprint of AI and aims to deploy carbon-efficient solutions. However, access to data and collaboration with domain experts are key roadblocks in utilizing AI to fight climate change, and safety considerations are addressed by working closely with experts in the respective fields. Overall, the techno-optimist view is that AI can be a transformative tool to solve climate change problems quickly and at scale.
